<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185003</url>
  </required_header>
  <id_info>
    <org_study_id>PP02</org_study_id>
    <secondary_id>ZONMW grant 907-00-056</secondary_id>
    <nct_id>NCT00185003</nct_id>
  </id_info>
  <brief_title>Blockade of Vascular Potassium Channels During Human Endotoxemia</brief_title>
  <official_title>Blockade of Vascular Potassium Channels During Human Endotoxemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Activation of NO-synthase and vascular potassium (K) channels may play a role in
      the sepsis-induced attenuated sensitivity to norepinephrine. We examined whether various K
      channel blockers and NO-synthase inhibition could restore norepinephrine sensitivity during
      experimental human endotoxemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>24 hrs after LPS administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of Inflammation</measure>
    <time_frame>24 hrs after LPS administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines</measure>
    <time_frame>24 hrs after LPS administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of Renal Injury</measure>
    <time_frame>24 hrs after LPS administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inducible NO synthase expression</measure>
    <time_frame>24 hrs after LPS administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NO-metabolites</measure>
    <time_frame>24 hrs after LPS administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mediators of Vascular reactivity</measure>
    <time_frame>24 hrs after LPS administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity to norepinephrine</measure>
    <time_frame>24 hrs after LPS administration</time_frame>
  </primary_outcome>
  <enrollment type="Actual">36</enrollment>
  <condition>Endotoxemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endotoxin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium channel blockers: TEA, Quinin, Tolbutamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-NMMA</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

        Exclusion Criteria:

          -  drug, alcohol, nicotine abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Pickkers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Pickkers P, Dorresteijn MJ, Bouw MP, van der Hoeven JG, Smits P. In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia. Circulation. 2006 Aug 1;114(5):414-21. Epub 2006 Jul 24.</citation>
    <PMID>16864730</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <keyword>Endotoxemia</keyword>
  <keyword>vascular potassium channels</keyword>
  <keyword>cytokine</keyword>
  <keyword>norepinephrine</keyword>
  <keyword>regional blood flow,</keyword>
  <keyword>inflammation,</keyword>
  <keyword>ion channels,</keyword>
  <keyword>nitric oxide synthase,</keyword>
  <keyword>pharmacology.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolbutamide</mesh_term>
    <mesh_term>Potassium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

